We are a clinical-stage pharmaceutical company developing novel therapeutics in oncology based on our expertise in lipid biology. Our lead product candidate, TVB-2640, is an oral, highly potent, selective and reversible, first-in-class inhibitor of FASN. We are currently evaluating TVB-2640 as monotherapy and in combination with paclitaxel in a Phase 1 clinical trial for the treatment of solid tumors, including non-small cell lung cancer (NSCLC), breast cancer and ovarian cancer.
Tumor cells depend on their ability to produce their own lipids; conversely, most normal cells in adults acquire their lipids from extracellular sources. The central enzyme of this process of lipid synthesis, or lipogenesis, is our first target, called Fatty Acid Synthase or FASN. Our lead product candidate is an internally discovered and developed inhibitor of FASN.
Lipids are integral to cellular metabolism, cellular signaling and cellular structure and the emerging understanding of lipid biology opens up promising new areas for drug development. With the recent advent of technologies that allow the characterization and manipulation of the lipidome, we believe we are poised to deliver important therapeutic advances. Together with a group of world-renowned experts in lipid biology, we have established expertise to translate this biology into patient benefit with a focus on oncology drug development.